A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : iCCA / intrahepatic cholangiocarcinoma

[Related PubMed/MEDLINE]
Total Number of Papers: 75
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   iCCA  (>> Co-occurring Abbreviation)
Long Form:   intrahepatic cholangiocarcinoma
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. AE, FGFR2
2019 Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma. DFS, lncRNA
2019 Genetic features associated with 18F-FDG uptake in intrahepatic cholangiocarcinoma. 18F-FDG
2019 Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma. pCCA
2019 Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma. CNAs, IDH1
2019 Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. CCA
2019 Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar post-operative clinical course but have distinct genetic features. HCC
2019 Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. AEs, hPFS, ORR, OS, PFS, PHP
2019 Remodelling and Improvements in Organoid Technology to Study Liver Carcinogenesis in a Dish. HCC, PLC
10  2019 Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection. AFP, HBV, OS
11  2019 Surgery For Cholangiocarcinoma. pCCA
12  2018 A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma. CASC15, TGF-beta, TLINC
13  2018 Alpha-L-Fucosidase Serves as a Prognostic Indicator for Intrahepatic Cholangiocarcinoma and Inhibits Its Invasion Capacity. AFU, OS, ROC
14  2018 Association of IRS2 overexpression with disease progression in intrahepatic cholangiocarcinoma. EMT, IRS2
15  2018 Baseline Volumetric Multiparametric MRI: Can It Be Used to Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma Undergoing Transcatheter Arterial Chemoembolization? ADC, HR, OS, TACE
16  2018 Challenges of surgical management of intrahepatic cholangiocarcinoma. ---
17  2018 Effects of liver cirrhosis and patient condition on clinical outcomes in intrahepatic cholangiocarcinoma: a retrospective analysis of 156 cases in a single center. ---
18  2018 Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. ---
19  2018 Evaluation of the AJCC 8th Edition Staging System for Pathologically Versus Clinically Staged Intrahepatic Cholangiocarcinoma (iCCA): a Time to Revisit a Dogma? A Surveillance, Epidemiology, and End Results (SEER) Analysis. c-indices, SEER
20  2018 Expression of VEGFR-3 in intrahepatic cholangiocarcinoma correlates with unfavorable prognosis through lymphangiogenesis. MLVD
21  2018 Foreign body granuloma reaction following SIRT mimicking peritoneal metastases: a word of caution. SIRT
22  2018 Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. HCC
23  2018 Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. BilIN, HCC
24  2018 Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. GemCis, mGPS, NLR, OS, PFS, PLR
25  2018 Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014. CIs, HRs
26  2018 Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014. CIs, HRs
27  2018 Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. AFP, AUC, CA19-9, HCC, PSC
28  2018 SHMT2 Overexpression Predicts Poor Prognosis in Intrahepatic Cholangiocarcinoma. IHC, SHMT2
29  2018 SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance. SRY-box
30  2018 Subcentimetric Incidental Intrahepatic Cholangiocarcinoma in an Explant Liver: Diagnostic Difficulty of a Rare Entity. ---
31  2018 Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma. CD
32  2018 Unresectable Intrahepatic Cholangiocarcinoma: Multiparametric MR Imaging to Predict Patient Survival. ADC, MR, mRECIST, RECIST, TACE
33  2018 Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. H-ChC, HCC, ITH
34  2017 A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. AST, RP2D
35  2017 Activation of Fas/FasL pathway and the role of c-FLIP in primary culture of human cholangiocarcinoma cells. PBMCs
36  2017 C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis. CRP
37  2017 Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center. anti-HCV, HBsAg, HBV, HCC, HCV, PLC
38  2017 CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma. ---
39  2017 Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing. lncRNAs
40  2017 Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: A meta-regression study. SIRT
41  2017 Intrahepatic cholangiocarcinoma: current management and emerging therapies. ---
42  2017 Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. ---
43  2017 Intratumoral heterogeneity of intrahepatic cholangiocarcinoma. ---
44  2017 Liver Cancer Cell of Origin, Molecular Class, and Effects onPatient Prognosis. HCC
45  2017 Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. ALDH, HBV, HCC, HCV
46  2017 Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. CLC, HCC, HCC-CCA, IGF, NCAM, SALL4, TGF
47  2017 Molecular and cytogenomic profiling of hepatic adenocarcinoma expressing inhibinA, a mimicker of neuroendocrine tumors: proposal to reclassify as "cholangioblastic variant of intrahepatic cholangiocarcinoma". ChrA, HCC, IHC, NET, NGS, SYN
48  2017 Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets. ---
49  2017 Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. FGFR4, HCC
50  2017 Mutations of candidate tumor suppressor genes at chromosome 3p in intrahepatic cholangiocarcinoma. TSGs
51  2017 Targeted therapy in biliary tract cancers-current limitations and potentials in the future. BTC, CCA, ECCA, GBC
52  2017 Therapeutic options for intrahepatic cholangiocarcinoma. BTC, ECCA
53  2017 [Biliary tract cancers : Molecular characterization and identification of novel prognostic markers]. BTCs, ECCA, GBC
54  2016 Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. FGFR2, PDX
55  2016 Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. BTC, dCCA, GWAS, pCCA
56  2016 Cystic and Papillary Neoplasm at the Hepatic Hilum Possibly Originating in the Peribiliary Glands. ---
57  2016 Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. NGS
58  2016 Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. OS
59  2016 Intrahepatic Cholangiocarcinoma in the Liver Explant After Liver Transplantation: Histological Differentiation and Prognosis. HCC, RFS
60  2016 Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. ---
61  2016 Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma. ---
62  2016 Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. ---
63  2016 Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection. ---
64  2016 Multimodality treatment of intrahepatic cholangiocarcinoma: A review. ---
65  2016 Overexpression of PDZK1IP1, EEF1A2 and RPL41 genes in intrahepatic cholangiocarcinoma. ---
66  2015 Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. HCC
67  2015 Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition. EMT
68  2015 Molecular diagnosis of intrahepatic cholangiocarcinoma. ---
69  2015 Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma. CN, CUL4A, IRS2, TFDP1
70  2015 Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation. HCC, LT
71  2014 "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? LT
72  2013 Unrecognized intrahepatic cholangiocarcinoma: an analysis of 993 adult cirrhotic liver explants. HCC, LT
73  2012 Surgical management of proximal bile duct cancers. HCCA
74  2010 Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. CT, RFA, US
75  2008 Intraductal oncocytic papillary neoplasm of the liver: case and review of a rare variant. CCA, OLT